Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
1000 participants
OBSERVATIONAL
2025-07-31
2028-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study plans to enroll elderly individuals from communities around Peking University Third Hospital to establish a prospective cohort. Participants will undergo cognitive assessments and blood biomarker testing, followed by a three-year follow-up and management program. The study aims to obtain epidemiological data on MCI and AD in community populations, investigate the relationships between known risk factors, genetic factors, and blood biomarkers with disease progression, explore additional biomarkers, and develop predictive models. These efforts will contribute to promoting early diagnosis, early intervention, and improved prognosis.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
China Alzheimer's and Neurodegenerative Disorder Research
NCT04320368
Cognitive Impairment in Ageing People
NCT04360200
The China Longitudinal Aging Study of Cognitive Impairment
NCT03672448
Cognitive Decline in AD
NCT03946930
Cognitive Impairment Cohort Study of the Elderly Population in YuGarden
NCT06325527
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. No diagnosis of Alzheimer's disease (AD);
3. Participants are able to complete cognitive tests, provide biological samples, undergo neuroimaging examinations, and cooperate throughout the entire study process;
4. Signed informed consent.
Exclusion Criteria
2. Participants who are unable to complete the required assessments due to visual or hearing impairments;
3. Contraindications for MRI or other study-related examinations.
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Peking University Third Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Qiong Yang
Role: PRINCIPAL_INVESTIGATOR
Peking University Third Hospital
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
M20250361
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.